Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Establishment Labs Announces Participation in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference


Business Wire | Feb 3, 2021 08:00AM EST

Establishment Labs Announces Participation in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Feb. 03, 2021

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Feb. 03, 2021--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan Jos Chacn-Quirs and Chief Financial Officer Renee Gaeta will participate in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference, which is being held February 17-19, 2021. Mr. Chacn-Quirs and Mrs. Gaeta are scheduled to speak to conference attendees at 10:00 am ET on Friday, February 19, 2021.

A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants(r), the centerpiece of the MotivaImagine(r) platform. Motiva Implants(r) are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company's direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant(r) clinical trial in the United States in April 2018. In addition to Motiva Implants(r), Establishment Labs' product and technologies portfolio includes the Divina(r) 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005068/en/

CONTACT: Investor/Media Contact: Renee Gaeta 818-326-6936 ir@establishmentlabs.com






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC